Viewing Study NCT06716658


Ignite Creation Date: 2025-12-25 @ 12:14 AM
Ignite Modification Date: 2025-12-25 @ 10:16 PM
Study NCT ID: NCT06716658
Status: RECRUITING
Last Update Posted: 2025-11-18
First Post: 2024-11-29
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module